A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

Exclusion Criteria

• •Any condition possibly affecting drug absorption
• •At screening, a positive result for HIV antibodies.
• •Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or participants with suspected MTC per study doctor's judgement.
• •History of acute pancreatitis within 6 months before the screening visit or any history of chronic pancreatitis.
• •Other medical or psychiatric condition or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
• •Use of specific prohibited prior/concomitant therapies
• •Use of an investigational product within 30 days (or local requirement) or 5 half-lives (whichever longer).
• •eGFR\<60 mL/min/1.73m2 at screening.
• •A positive urine drug test at screening or admission to study clinic.
• •At screening or admission to study clinic, a positive breath alcohol test.
• •For females, pregnancy, as indicated by a positive serum pregnancy test at screening and/or positive urine pregnancy test in women capable of having children at admission to study clinic
• •Group 1 only: evidence of chronic liver disease including history of hepatitis, hepatitis B, or hepatitis C.
• •Group 1 only: history of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of screening.
• •Group 1 only: screening ECG demonstrating QTcF interval \>450 ms or a QRS interval \>120 ms.
• •Group 1 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
• •Group 1 only: use of chronic prescription medications within 7 days or 5 half-lives (whichever longer) before Day 1, or for prohibited medications, use within the required washout/restriction period.
• •Group 2, 3 \& 4 only: Hepatic carcinoma or hepatorenal syndrome or limited predicted life expectancy (defined as \<1 year in Groups 2 \& 3 and \<6 months for Group 4 only).
• •Group 2, 3 \& 4 only: a diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, physical exam, liver biopsy, hepatic ultrasound, CT scan, or MRI.
• •Group 2, 3 \& 4 only: history of surgery that would be expected to alter absorption, distribution, metabolism, or excretion properties of PF-07081532.
• •Group 2, 3 \& 4 only: history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 4 weeks prior to screening.
• •Group 2, 3 \& 4 only: signs of clinically active Grade 3 or 4 hepatic encephalopathy
• •Groups 2, 3 \& 4 only: severe ascites and/or pleural effusion, except for those categorized in Group 4 who may be enrolled provided participant is medically stable, per the study doctor's judgment.
• •Groups 2, 3 \& 4 only: previously received a kidney, liver, or heart transplant.
• •Groups 2, 3, \& 4 only: screening ECG demonstrating a QTcF interval \>470 ms or a QRS interval \>120 ms.
• •Groups 2, 3 \& 4 only: at screening, admission to study clinic or pre-dose on Day 1, persistent severe, uncontrolled hypertension.
• •Groups 2, 3 \& 4 only: ALT or AST \>5x upper limit of normal on clinical laboratory tests at screening.